Medical device maker sets FY 2027 net sales and adjusted EBITDA targets following Q4 FY 2026 earnings call.
AngioDynamics projected net sales of $336M-$341M for fiscal year 2027, alongside adjusted EBITDA guidance of $13M-$16M. The outlook was disclosed during the company’s Q4 FY 2026 earnings call.
The guidance follows a period of operational adjustments and strategic shifts within the company. Prior-year financials and market expectations were not detailed in the call, but the targets reflect management’s confidence in growth and profitability.
Shares of AngioDynamics (ANGO) showed limited immediate reaction to the announcement, as investors await further details on execution plans.